IL-1[alpha] Expression in Pancreatic Ductal Adenocarcinoma Affects the Tumor Cell Migration and Is Regulated by the p38MAPK Signaling Pathway

• Published in: PloS one 2013-08, Vol.8 (8), p.e70874
• Main Authors: Tjomsland, Vegard, Bojmar, Linda, Sandström, Per, Bratthäll, Charlotte, Messmer, Davorka, Spångeus, Anna, Larsson, Marie
• Format: Article
• Language: English
• Subjects: Adenocarcinoma; Genes; Inflammation; Pancreatic cancer
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0070874

The interplay between the tumor cells and the surrounding stroma creates inflammation, which promotes tumor growth and spread. The inflammation is a hallmark for pancreatic adenocarcinoma (PDAC) and is to high extent driven by IL-1[alpha]. IL-1[alpha] is expressed and secreted by the tumor cells and exerting its effect on the stroma, i.e. cancer associated fibroblasts (CAF), which in turn produce massive amount of inflammatory and immune regulatory factors. IL-1 induces activation of transcription factors such as nuclear factor-[kappa][beta] (NF-[kappa][beta]), but also activator protein 1 (AP-1) via the small G-protein Ras. Dysregulation of Ras pathways are common in cancer as this oncogene is the most frequently mutated in many cancers. In contrast, the signaling events leading up to the expression of IL-1[alpha] by tumor cells are not well elucidated. Our aim was to examine the signaling cascade involved in the induction of IL-1[alpha] expression in PDAC. We found p38MAPK, activated by the K-Ras signaling pathway, to be involved in the expression of IL-1[alpha] by PDAC as blocking this pathway decreased both the gene and protein expression of IL-1[alpha]. Blockage of the P38MAPK signaling in PDAC also dampened the ability of the tumor cell to induce inflammation in CAFs. In addition, the IL-1[alpha] autocrine signaling regulated the migratory capacity of PDAC cells. Taken together, the blockage of signaling pathways leading to IL-1[alpha] expression and/or neutralization of IL-1[alpha] in the PDAC microenvironment should be taken into consideration as possible treatment or complement to existing treatment of this cancer.